- Home
- ZH vs BNTC Comparison
ZH vs BNTC Comparison
Compare ZH & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZH | BNTC |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.6M | 365.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZH | BNTC |
|---|---|---|
| Price | $3.49 | $13.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.70 | ★ $26.00 |
| AVG Volume (30 Days) | 216.3K | ★ 260.9K |
| Earning Date | 11-25-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $416,437,241.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.19 | $9.70 |
| 52 Week High | $6.32 | $17.15 |
Technical Indicators
Market Signals| Indicator | ZH | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 30.45 | 48.76 |
| Support Level | $3.42 | $11.54 |
| Resistance Level | $4.14 | $13.68 |
| Average True Range (ATR) | 0.17 | 0.79 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 12.50 | 73.44 |
Price Performance
Historical ComparisonAbout ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.